Username:
Password:
Enter your email below to subscribe to our Health & Biotech News Digest.

All News

Jan 25, 2008
HyperMed receives 510K approval to market its second-generation device, OxyVu-2 for use in determining oxygenation levels in tissue for patients with potential circulatory compromise
Burlington, MA – January 25, 2008 – HyperMed has just received U.S. Food and Drug Administration (FDA) approval to legally market its second-generation diagnostic device, the OxyVu™-2. The non-invasive OxyVu™-2 Hyperspectral Tissue Oxygenation Measurement System (HTCOM Read More...
Filed Under: Company News



Dec 20, 2007
GBP IP, LLC Acquires Lentiviral Gene Delivery Technology from Cell Genesys
Cell Genesys, Inc. (Nasdaq: CEGE) and GBP IP, LLC, an affiliate of GBP Capital, the majority shareholder in privately held Lentigen Corporation, today announced that the two companies have entered into an asset sale agreement relating to Cell Genesys' lentiviral gene delivery technology, commonl Read More...
Filed Under: GBP Captial News



Nov 03, 2007
Spectral Image, Inc. Receives $5 Million Series A from GBP Capital
Greenwich, CT and Tampa, FL November 3, 2007 -- Spectral Image Inc., a privately held early stage medical device company focused on the development of imaging technology for biomedical use, today announced the completion of a $5 million Series A venture financing with GBP Capital. At th Read More...
Filed Under: Company News



Sep 17, 2007
Lentigen Partners with Thermo Fisher Scientific to Offer Revolutionary SMARTvector shRNA Lentiviral Particles for Gene Silencing
  Baltimore, MD, September 17, 2007   Thermo Fisher Scientific Inc., the world leader in serving science, has partnered with Lentigen Corporation, a renowned developer of lentiviral vector gene-delivery systems, to launch Thermo Scientific Dharmacon SMARTvector shRNA Read More...
Filed Under: Company News



Jun 20, 2007
Lentigen Corporation Named Best Life Science Company in 7th Annual Maryland Incubator Company of the Year Awards
  Baltimore, MD, June 20, 2007   Lentigen Corporation, a privately held biotechnology company focused on the manufacturing and development of lentiviral vectors, announced today that it has been named Best Life Science Company in the 7th Annual Maryland Incubator C Read More...
Filed Under: Company News



Feb 28, 2007
HyperMed, Inc. Receives $5 Million Series A from Greenwich Biotech Partners
  Waltham, MA- February 28, 2007  HyperMed, Inc., the leader in hyperspectral medical imaging, today announced it has secured $5 million in Series A financing from Greenwich Biotech Partners. Proceeds from this financing will be used to market, sell and support HyperMe Read More...
Filed Under: Company News



Feb 28, 2007
HyperMed, Inc. Announces the Addition of Two Directors to its Board
  Waltham, MA - February 28, 2007    HyperMed, Inc., the leader in hyperspectral medical imaging, today announced the addition of Douglas Lind, MD and Bruce Ryan, PhD to the HyperMed Board of Directors, joining founders Jenny Fr Read More...
Filed Under: Company News



Jan 25, 2007
Lentigen Corporation and Wave Biotech, LLC Announce Formation of Collaboration
  Baltimore, MD and Somerset, NJ January 25, 2007    Lentigen Corporation and Wave Biotech, LLC announced today that they have entered into a collaboration under which Wave Biotech will provide process and equipment expertise for Lentigen’s manufacturing pl Read More...
Filed Under: Company News



Dec 04, 2006
Lentigen Corporation Named Technology Pioneer for 2007 by The World Economic Forum
    BALTIMORE, MD, DECEMBER 4, 2006   The World Economic Forum today named Lentigen Corporation one of 47 Technology Pioneers for 2007. A panel of top technology experts appointed by the World Economic Forum made the final selection from 225 ca Read More...
Filed Under: Company News



Nov 30, 2006
Lentigen Corporation Receives Grant From the NIH To Develop a Potential New Therapy For The Treatment of Chronic Lymphocytic Leukemia
  Baltimore, MD and Philadelphia, PA November 30, 2006     Lentigen Corporation announced today that it has received National Institute of Health (NIH) Small Business Innovation Research (SBIR) funding to develop an improved and nove Read More...
Filed Under: Company News



57 results:

<<123456>>


© 2007 GBP Capital. All Rights Reserved. Legal | Privacy Statement | Sitemap